Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies
Sander B. Frank, Thomas W. Persse, I. M. Coleman, Armand Bankhead, Dapei Li, Navonil De Sarkar, Divin Wilson, Dmytro Rudoy, Manasvita Vashisth, Patty Galipeau, Michael Yang, Brian P. Hanratty, Ruth F. Dumpit, Colm M. Morrissey, Eva Corey, , Peter S. Nelson
This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.
bioRxiv · Jul 16, 2024 · PreprintCancer Biology